ClinicalTrials.gg
CompletedNCT03398148Updated Jan 16, 2025Results posted

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3 interventional study of risankizumab IV and placebo for risankizumab in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 430 sites in 44 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,558
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.

Enrollment
2nd of 31
1,558 · median 156
Started
2018
with 2 others
Phase 2/3
2 of 53
none open now
Registered
27th of 53
by date

Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2/3, and was the 27th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colitis, Ulcerative by AbbVie, or all of them as a file.
02

Study summary

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2.

The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged >=18 to \<= 80 years at the Baseline Visit. Where locally permissible, subjects 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
  • Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to Baseline.
  • Active UC as assessed by Adapted Mayo Score and Endoscopic Subscore.
  • Demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies.
  • Females must be for more than 1 year or surgically sterile or practicing specific forms of .

Exclusion criteria

Exclusion Criteria:

  • Participant with a current diagnosis of Crohn's disease (CD), inflammatory bowel disease-unclassified (IBD-U) or a history of radiation colitis or ischemic colitis.
  • Participant receiving prohibited medications and treatment.
  • Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy.
  • Participant with currently known complications of UC (e.g., megacolon).
  • No known active Coronavirus Disease - 2019 (COVID-19) infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,558 participants (actual)

Study arms

  • Placebo comparator
    Substudy 1, Induction Period 1: Double-blind Placebo IV

    Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.

    Drug: placebo for risankizumab

  • Experimental
    Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV

    Participants randomized to receive risankizumab 600mg administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV

    Participants randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV

    Participants randomized to receive risankizumab 1800mg administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV

    Participants receive risankizumab 1800mg administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 180mg administered by subcutaneous (SC) injection in Induction 2.

    Drug: risankizumab SC

  • Experimental
    Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 360mg administered by subcutaneous (SC) injection in Induction 2.

    Drug: risankizumab SC

  • Experimental
    Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 1800mg administered by intravenous (IV) infusion in Induction 2.

    Drug: risankizumab IV

  • Experimental
    Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo

    Participants who received placebo with inadequate response in Induction 1 receive risankizumab 1800mg administered by intravenous (IV) infusion in Induction 2.

    Drug: risankizumab IV

  • Placebo comparator
    Substudy 2, Induction Period 1: Double-blind Placebo IV

    Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.

    Drug: placebo for risankizumab

  • Experimental
    Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV

    Participants randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion.

    Drug: risankizumab IV

  • Experimental
    Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 180mg administered by subcutaneous (SC) injection in Induction 2.

    Drug: risankizumab SC

  • Experimental
    Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 360mg administered by subcutaneous (SC) injection in Induction 2.

    Drug: risankizumab SC

  • Experimental
    Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV

    Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion in Induction 2.

    Drug: risankizumab IV

  • Experimental
    Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo

    Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab 1200mg administered by intravenous (IV) infusion in Induction 2.

    Drug: risankizumab IV

Interventions

  • risankizumab intravenous (IV) infusion

    Also known as: ABBV-066, BI 655066

  • Drugplacebo for risankizumab

    placebo for risankizumab

  • risankizumab subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066

06

What researchers measure

Primary outcomes

  1. Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 1, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1.

    Time frame: Week 12

  2. Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 2, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1. Evidence of friability during endoscopy in subjects with otherwise "mild" endoscopic activity will confer an endoscopic subscore of 2.

    Time frame: Week 12

Secondary outcomes

  1. Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement

    Endoscopic improvement is defined as endoscopy subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 12

  2. Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Full Mayo Score in Participants With a Full Mayo Score of 6 to 12 at Baseline

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Week 12

  3. Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response per Adapted Mayo Score was defined as decrease from baseline in Adapted Mayo Score ≥ 2 points and ≥ 30%, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

    Time frame: Week 12

  4. Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score

    Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score \>= 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

    Time frame: Week 4

  5. Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission

    Endoscopic remission was defined as endoscopy subscore of 0.

    Time frame: Week 12

  6. Sub-Study 1: Percentage of Participants With Hospitalization

    Participants with an event that results in admission to the hospital.

    Time frame: Through Week 12

  7. Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)

    Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: Week 12

  8. Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

    The US-SQ is a patient questionnaire to assess severity of Ulcerative Colitis (UC) related gastrointestinal symptoms (e.g., frequent bowel movements, abdominal pain, cramping) and non-gastrointestinal symptoms (e.g., joint pain and sleep difficulties). It consists of 17 questions and each question is answered on a scale from can be answered on a scale from 1 (Not at all/ never) to 5 (Very much/Always) with overall symptom score range from 17 to 85. A lower score indicates lower UC severity.

    Time frame: Baseline Through Week 12

  9. Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

    The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

    Time frame: Baseline Through Week 12

  10. Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component

    The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

    Time frame: Baseline Through Week 12

  11. Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component

    The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

    Time frame: Baseline through Week 12

  12. Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Baseline Through Week 12

  13. Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries

    Participants who underwent surgery related to UC.

    Time frame: Through Week 12

  14. Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical Response is defined as a decrease from baseline in the Adapted Mayo Score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

    Time frame: Week 12

  15. Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement

    Endoscopic Improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 12

  16. Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)

    Histologic-Endoscopic Mucosal Improvement is defined as an endoscopic subscore of 0 or 1 without evidence of friability and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: Week 12

  17. Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission

    Endoscopic remission per endoscopy subscore. Endoscopic Remission: endoscopic subscore = 0.

    Time frame: Week 12

  18. Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4

    Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical Response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo Score ≥ 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

    Time frame: Week 4

  19. Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency

    Percentage of participants who reported no bowel urgency. Bowel urgency was assessed by participants in a subject diary completed once a day.

    Time frame: Week 12

  20. Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain

    Percentage of participants who reported no abdominal pain. Abdominal pain was assessed by participants in a subject diary completed once a day.

    Time frame: Week 12

  21. Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12

    Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: Week 12

  22. Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Baseline to Week 12

  23. Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

    Time frame: Baseline to Week 12

  24. Sub-Study 2: Occurrence of UC-related Hospitalizations

    Participants with an UC-related event that results in admission to the hospital.

    Time frame: Baseline Through Week 12

  25. Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements

    Percentage of participants who reported no nocturnal bowel movements.

    Time frame: Week 12

  26. Sub-Study 2: Percentage of Participants Achieving No Tenesmus

    Percentage of participants who reported no tenesmus.

    Time frame: Week 12

  27. Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week

    Change in number of fecal incontinence episodes per week.

    Time frame: Baseline to Week 12

  28. Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms

    Change from baseline in number of days per week with sleep interrupted due to UC symptoms.

    Time frame: Baseline to Week 12

07

Results

Posted Jan 16, 2025

Participant flow

Substudy 1 Period 1
Participant flow — Substudy 1 Period 1
MilestoneSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo
Started606161583410000000000
Completed535558573060000000000
Not completed7631350000000000
Withdrew: Adverse event522080000000000
Withdrew: Withdrew consent120130000000000
Withdrew: Lack of efficacy1110200000000000
Withdrew: Other010030000000000
Withdrew: Enrolled but not treated000010000000000
Substudy 1 Period 2
Participant flow — Substudy 1 Period 2
MilestoneSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo
Started0000072703637000000
Completed0000065573435000000
Not completed0000071322000000
Withdrew: Adverse event000002400000000
Withdrew: Withdrew consent000000120000000
Withdrew: Lack of efficacy000005502000000
Withdrew: Covid-19 logistical restrictions000000100000000
Withdrew: Other000000100000000
Withdrew: Enrolled but not treated000000100000000
Substudy 2 Period 1
Participant flow — Substudy 2 Period 1
MilestoneSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo
Started0000000003256520000
Completed0000000002976370000
Not completed00000000028150000
Withdrew: Adverse event0000000001220000
Withdrew: Withdrew consent000000000640000
Withdrew: Lack of efficacy000000000610000
Withdrew: Covid-19 infection000000000010000
Withdrew: Covid-19 logistical restrictions000000000010000
Withdrew: Other000000000440000
Withdrew: Enrolled but not treated000000000020000
Substudy 2 Period 2
Participant flow — Substudy 2 Period 2
MilestoneSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo
Started00000000000717168174
Completed00000000000656561164
Not completed0000000000066710
Withdrew: Adverse event000000000000013
Withdrew: Lost to follow-up000000000001100
Withdrew: Withdrew consent000000000004021
Withdrew: Lack of efficacy000000000001434
Withdrew: Other000000000000011
Withdrew: Enrolled but not treated000000000000101

Outcome measures

PrimarySub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 1, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score176642
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.0324 (P-value ≤ 0.05) · Adjusted risk difference: 9.6 · 90% CI 2.2 to 17.0Risk difference = (risankizumab - Placebo)
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0460 (P-value ≤ 0.05) · Adjusted risk difference: 8.4 · 90% CI 1.5 to 15.3Risk difference = (risankizumab - Placebo)
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = 0.0397 (P-value ≤ 0.05.) · Adjusted risk difference: 8.7 · 90% CI 1.7 to 15.6Risk difference = (risankizumab - Placebo).
PrimarySub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Sub-Study 2, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1. Evidence of friability during endoscopy in subjects with otherwise "mild" endoscopic activity will confer an endoscopic subscore of 2.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score6.2 (3.6 to 8.9)20.3 (17.2 to 23.4)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Type I error rate control.) · Adjusted risk difference: 14.0 · 95% CI 10.0 to 18.0Stratified by Advanced Therapy-IR status (yes vs no), Baseline steroid use (yes vs. no) and Baseline Adapted Mayo Score (≤ 7, \> 7).
SecondarySub-Study 1: Percentage of Participants Achieving Endoscopic Improvement

Endoscopic improvement is defined as endoscopy subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement3158961
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.0028 (P-value ≤ 0.01) · Adjusted risk difference: 18.7 · 90% CI 8.4 to 29.0Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0968 (P-value ≤ 0.1) · Adjusted risk difference: 8.4 · 90% CI 0.1 to 16.7Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = 0.0512 (P-value ≤ 0.1) · Adjusted risk difference: 10.5 · 90% CI 1.6 to 19.3Risk difference = (risankizumab - Placebo).
SecondarySub-Study 1: Percentage of Participants Achieving Clinical Remission Per Full Mayo Score in Participants With a Full Mayo Score of 6 to 12 at Baseline

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondarySub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response per Adapted Mayo Score was defined as decrease from baseline in Adapted Mayo Score ≥ 2 points and ≥ 30%, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score12262831157
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.0022 (P-value ≤ 0.01) · Adjusted risk difference: 23.9 · 90% CI 11.0 to 36.7Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0002 (P-value ≤ 0.001) · Adjusted risk difference: 28.4 · 90% CI 15.7 to 41.1Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (P-value ≤ 0.001) · Adjusted risk difference: 33.8 · 90% CI 20.7 to 46.9Risk difference = (risankizumab - Placebo).
SecondarySub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score

Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score \>= 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score15202822148
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.1842 · Adjusted risk difference: 10.2 · 90% CI -2.4 to 22.9Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0041 (P-value ≤ 0.01) · Adjusted risk difference: 23.2 · 90% CI 9.9 to 36.4Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = 0.1117 · Adjusted risk difference: 13.1 · 90% CI -0.4 to 26.6Risk difference = (risankizumab - Placebo).
SecondarySub-Study 1: Percentage of Participants Achieving Endoscopic Remission

Endoscopic remission was defined as endoscopy subscore of 0.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission053522
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.0192 (P-value ≤ 0.05) · Adjusted risk difference: 8.3 · 90% CI 2.5 to 14.1Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0706 (P-value ≤ 0.1) · Adjusted risk difference: 4.8 · 90% CI 0.4 to 9.1Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = 0.0170 (P-value ≤ 0.05) · Adjusted risk difference: 8.7 · 90% CI 2.7 to 14.6Risk difference = (risankizumab - Placebo).
SecondarySub-Study 1: Percentage of Participants With Hospitalization

Participants with an event that results in admission to the hospital.

Time frame:
Through Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants With Hospitalization
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants With Hospitalization564319
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Chi-squared · p = 0.7737P value for comparisons between treatment groups and placebo group using chi-square test or Fisher's exact test.
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Fisher Exact · p = 0.7432P value for comparisons between treatment groups and placebo group using chi-square test or Fisher's exact test.
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Fisher Exact · p = 0.7172P value for comparisons between treatment groups and placebo group using chi-square test or Fisher's exact test.
SecondarySub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)

Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)032110
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Cochran-Mantel-Haenszel · p = 0.0722 (P-value ≤ 0.1) · Adjusted risk difference: 4.7 · 90% CI 0.4 to 9.0Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.1480 · Adjusted risk difference: 3.1 · 90% CI -0.4 to 6.6Risk difference = (risankizumab - Placebo).
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Cochran-Mantel-Haenszel · p = 0.3042 · Adjusted risk difference: 1.7 · 90% CI -1.0 to 4.5Risk difference = (risankizumab - Placebo).
SecondarySub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

The US-SQ is a patient questionnaire to assess severity of Ulcerative Colitis (UC) related gastrointestinal symptoms (e.g., frequent bowel movements, abdominal pain, cramping) and non-gastrointestinal symptoms (e.g., joint pain and sleep difficulties). It consists of 17 questions and each question is answered on a scale from can be answered on a scale from 1 (Not at all/ never) to 5 (Very much/Always) with overall symptom score range from 17 to 85. A lower score indicates lower UC severity.

Time frame:
Baseline Through Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)
units on a scaleSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)-7.4 ± 1.53-13.8 ± 1.50-15.6 ± 1.46-15.1 ± 1.51-17.1 ± 0.58
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Mixed-effect model repeated measurement · p = 0.0030 (P-value ≤ 0.01) · Least squares (ls) mean difference: -6.4 · 90% CI -9.94 to -2.89
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-effect model repeated measurement · p = 0.0001 (P-value ≤ 0.001) · Least squares (ls) mean difference: -8.2 · 90% CI -11.67 to -4.71
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Mixed-effect model repeated measurement · p = 0.0004 (P-value ≤ 0.001) · Least squares (ls) mean difference: -7.7 · 90% CI -11.27 to -4.19
SecondarySub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

Time frame:
Baseline Through Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
units on a scaleSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)20.1 ± 4.6737.4 ± 4.5640.3 ± 4.3840.0 ± 4.5549.5 ± 1.86
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Mixed-effect model repeated measurement · p = 0.0081 (P-value ≤ 0.01) · Least squares (ls) mean difference: 17.3 · 90% CI 6.61 to 28
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-effect model repeated measurement · p = 0.0017 (P-value ≤ 0.01) · Least squares (ls) mean difference: 20.3 · 90% CI 9.74 to 30.79
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Mixed-effect model repeated measurement · p = 0.0024 (P-value ≤ 0.01) · Least squares (ls) mean difference: 19.9 · 90% CI 9.22 to 30.67
SecondarySub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component

The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

Time frame:
Baseline Through Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component
units on a scaleSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component3.904 ± 0.89075.112 ± 0.87516.350 ± 0.83416.296 ± 0.86757.719 ± 0.3929
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Mixed-effect model repeated measurement · p = 0.3315 · Least squares (ls) mean difference: 1.208 · 90% CI -0.8429 to 3.2596
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-effect model repeated measurement · p = 0.0451 (P-value ≤ 0.05) · Ls mean of difference: 2.447 · 90% CI 0.4415 to 4.4519
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Mixed-effect model repeated measurement · p = 0.0543 (P-value ≤ 0.1) · Ls mean of difference: 2.392 · 90% CI 0.3498 to 4.4352
SecondarySub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component

The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · unites on a scale
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component
unites on a scaleSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component3.094 ± 1.25336.756 ± 1.23197.284 ± 1.17395.442 ± 1.21857.777 ± 0.4777
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Mixed-effect model repeated measurement · p = 0.0367 (P-value \<= 0.1) · Ls mean of difference: 3.662 · 90% CI 0.7841 to 6.5402P-value for test of difference between each Risankizumab dose group and placebo for mean change from baseline using the mixed-effect repeated measure model The unstructured covariance structure was used to estimate within subject errors.
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-effect model repeated measurement · p = 0.0151 (P-value \<= 0.05) · Ls mean of difference: 4.190 · 90% CI 1.3656 to 7.0144P-value for test of difference between each Risankizumab dose group and placebo for mean change from baseline using the mixed-effect repeated measure model The unstructured covariance structure was used to estimate within subject errors.
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Mixed-effect model repeated measurement · p = 0.1795 · Ls mean of difference: 2.348 · 90% CI -0.5322 to 5.2281P-value for test of difference between each Risankizumab dose group and placebo for mean change from baseline using the mixed-effect repeated measure model The unstructured covariance structure was used to estimate within subject errors.
SecondarySub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Baseline Through Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
units on a scaleSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)3.7 ± 1.377.6 ± 1.359.0 ± 1.298.3 ± 1.3310.7 ± 0.54
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Mixed-effect model repeated measurement · p = 0.0422 (P-value ≤ 0.05) · Least squares (ls) mean difference: 3.9 · 90% CI 0.75 to 7.06
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-effect model repeated measurement · p = 0.0049 (P-value ≤ 0.01) · Least squares (ls) mean difference: 5.3 · 90% CI 2.23 to 8.42
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV · Mixed-effect model repeated measurement · p = 0.0156 (P-value ≤ 0.05) · Least squares (ls) mean difference: 4.6 · 90% CI 1.50 to 7.80
SecondarySub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries

Participants who underwent surgery related to UC.

Time frame:
Through Week 12
Reported as:
Count of participants · Participants
Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries
ParticipantsSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV
Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries01007
Statistical analysis
  • Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV · Fisher Exact · p = 1 (P-Value for comparisons between treatment groups and placebo group using Fisher's exact test.)
SecondarySub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. Clinical Response is defined as a decrease from baseline in the Adapted Mayo Score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score35.7 (30.5 to 40.9)64.3 (60.6 to 67.9)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 28.6 · 95% CI 22.3 to 34.8Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference.
SecondarySub-Study 2: Percentage of Participants Achieving Endoscopic Improvement

Endoscopic Improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement12.1 (8.5 to 15.6)36.5 (32.8 to 40.2)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 24.3 · 95% CI 19.3 to 29.4Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)

Histologic-Endoscopic Mucosal Improvement is defined as an endoscopic subscore of 0 or 1 without evidence of friability and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)7.7 (4.8 to 10.6)24.5 (21.2 to 27.8)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 16.6 · 95% CI 12.3 to 21.0Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving Endoscopic Remission

Endoscopic remission per endoscopy subscore. Endoscopic Remission: endoscopic subscore = 0.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission3.4 (1.4 to 5.4)10.6 (8.2 to 13.0)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 7.2 · 95% CI 4.2 to 10.2Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4

Clinical response per Partial Adapted Mayo Score (without endoscopy). The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) The overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease. Clinical Response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo Score ≥ 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 430.5 (25.5 to 35.5)52.2 (48.3 to 56.0)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 21.8 · 95% CI 15.6 to 28.1Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving No Bowel Urgency

Percentage of participants who reported no bowel urgency. Bowel urgency was assessed by participants in a subject diary completed once a day.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency27.7 (22.8 to 32.6)44.1 (40.3 to 47.9)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 16.3 · 95% CI 10.3 to 22.4Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving No Abdominal Pain

Percentage of participants who reported no abdominal pain. Abdominal pain was assessed by participants in a subject diary completed once a day.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain26.5 (21.7 to 31.3)35.8 (32.1 to 39.4)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = 0.0021 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 9.3 · 95% CI 3.4 to 15.3Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12

Mucosal healing defined as endoscopic and histologic remission. Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 120.6 (0.0 to 1.5)6.3 (4.4 to 8.2)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 5.6 · 95% CI 3.5 to 7.7Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale. 0 = not at all 1. = a little bit 2. = somewhat 3. = quite a bit 4. = very much The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
units on a scaleSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)3.3 (2.12 to 4.50)7.9 (7.03 to 8.69)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · ANCOVA · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Least squares (ls) mean difference: 4.5 · 95% CI 3.13 to 5.97Between-group diff. and 95% CI calculated using ANCOVA/MMRM with RTB-MI for continuous endpoints.
SecondarySub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · units on a scale
Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
units on a scaleSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score24.3 (20.19 to 28.46)42.6 (39.72 to 45.57)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · ANCOVA · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Least squares (ls) mean difference: 18.3 · 95% CI 13.38 to 23.25Between-group diff. and 95% CI calculated using ANCOVA/MMRM with RTB-MI for continuous endpoints.
SecondarySub-Study 2: Occurrence of UC-related Hospitalizations

Participants with an UC-related event that results in admission to the hospital.

Time frame:
Baseline Through Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Occurrence of UC-related Hospitalizations
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Occurrence of UC-related Hospitalizations5.5 (3.1 to 8.0)0.8 (0.1 to 1.4)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Chi-squared · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Risk difference (rd): -4.8 · 95% CI -7.3 to -2.295% CI for treatment differences is based on normal approximation of the binomial proportions.
SecondarySub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements

Percentage of participants who reported no nocturnal bowel movements.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements43.1 (37.7 to 48.5)67.3 (63.7 to 70.9)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 24.2 · 95% CI 17.9 to 30.5Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference. (Greenland and Robins (1985)).
SecondarySub-Study 2: Percentage of Participants Achieving No Tenesmus

Percentage of participants who reported no tenesmus.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Sub-Study 2: Percentage of Participants Achieving No Tenesmus
percentage of participantsSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Percentage of Participants Achieving No Tenesmus30.2 (25.2 to 35.1)48.7 (44.9 to 52.6)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Cochran-Mantel-Haenszel · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Adjusted risk difference: 18.6 · 95% CI 12.4 to 24.8Between-group diff. and 95% CI calculated using Mantel-Haenszel common rate difference.
SecondarySub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week

Change in number of fecal incontinence episodes per week.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Fecal Incontinence Episodes/ week
Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week
Fecal Incontinence Episodes/ weekSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week-2.213 (-2.8526 to -1.5726)-3.839 (-4.2687 to -3.4099)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-Effect Model Repeated Measures · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Least squares (ls) mean difference: -1.627 · 95% CI -2.3846 to -0.8689Between-group diff. and 95% CI calculated using ANCOVA/MMRM with RTB-MI for continuous endpoints.
SecondarySub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms

Change from baseline in number of days per week with sleep interrupted due to UC symptoms.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · days
Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms
daysSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV
Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms-1.505 (-1.7969 to -1.2122)-2.485 (-2.6872 to -2.2831)
Statistical analysis
  • Substudy 2, Induction Period 1: Double-blind Placebo IV vs Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV · Mixed-Effect Model Repeated Measures · p = <0.0001 (Statistical significance is determined via the graphical multiple testing procedure controlling the overall type I error rate of primary and key secondary endpoints at the 0.05 level.) · Least squares (ls) mean difference: -0.981 · 95% CI -1.3285 to -0.6326Between-group diff. and 95% CI calculated using ANCOVA/MMRM with RTB-MI for continuous endpoints.

Adverse events

Collected over In S1P1, median time on follow-up was 86, 86, 85, 87, & 87 days(d) for S1P1 DB-PboIV, S1P1 DB-Risankizumab(Risa) 600mgIV, S1P1 DB-Risa 1200mgIV, S1P1 DB-Risa 1800mgIV, and S1P1 OL-Risa 1800mgIV; respectively. In S1P2, median time on follow-up was 87, 106, 93 and 93 d for arms S1P2 DB -Risa 1800mgIVPbo, S1P2 DB-Risa1800mgIV, S1P2 DB-Risa 180mgSC, and S1P2 DB-Risa 360mgSC; respectively. In S2P1, median time on follow-up was 87 and 89d for arms S2P1 DB-PboIV, S2P1 DB Risa1200mgIV, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Substudy 1, Induction Period 1: Double-blind Placebo IV0/59 (0%)6/59 (10.2%)14/59 (23.7%)
Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV0/62 (0%)6/62 (9.7%)13/62 (21%)
Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV0/61 (0%)4/61 (6.6%)12/61 (19.7%)
Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV0/58 (0%)5/58 (8.6%)12/58 (20.7%)
Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV0/341 (0%)25/341 (7.3%)76/341 (22.3%)
Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo0/36 (0%)3/36 (8.3%)11/36 (30.6%)
Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV0/37 (0%)1/37 (2.7%)6/37 (16.2%)
Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC0/71 (0%)6/71 (8.5%)4/71 (5.6%)
Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC0/71 (0%)7/71 (9.9%)16/71 (22.5%)
Substudy 2, Induction Period 1: Double-blind Placebo IV0/324 (0%)34/324 (10.5%)64/324 (19.8%)
Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV1/653 (0.2%)17/653 (2.6%)101/653 (15.5%)
Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo0/174 (0%)4/174 (2.3%)23/174 (13.2%)
Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV0/68 (0%)1/68 (1.5%)9/68 (13.2%)
Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC0/71 (0%)4/71 (5.6%)10/71 (14.1%)
Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC0/71 (0%)1/71 (1.4%)23/71 (32.4%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV PboSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC
COLITIS ULCERATIVEGastrointestinal disorders3/591/620/610/5816/3411/360/373/712/7116/3243/6531/1740/681/711/71
ANAEMIABlood and lymphatic system disorders0/590/622/610/580/3410/360/370/711/712/3242/6530/1740/680/710/71
ERYSIPELASInfections and infestations0/590/620/610/580/3411/360/370/710/710/3240/6530/1740/680/710/71
LUNG ABSCESSInfections and infestations0/590/620/610/580/3411/360/370/710/710/3240/6530/1740/680/710/71
OSTEONECROSISMusculoskeletal and connective tissue disorders1/590/620/610/580/3411/360/370/710/710/3241/6530/1740/680/710/71
PEMPHIGOIDSkin and subcutaneous tissue disorders0/590/620/610/580/3411/360/370/710/710/3240/6530/1740/680/710/71
SALMONELLOSISInfections and infestations0/590/620/610/580/3410/361/370/710/710/3240/6530/1740/680/710/71
BLOOD LOSS ANAEMIABlood and lymphatic system disorders0/590/620/611/580/3410/360/370/710/710/3240/6530/1740/680/710/71
COLITISGastrointestinal disorders0/591/620/611/580/3410/360/370/710/710/3240/6530/1740/680/710/71
APPENDICITISInfections and infestations0/590/620/611/580/3410/360/370/710/711/3240/6530/1740/680/710/71
Most frequent other events
Most frequent other events
EventSubstudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV PboSubstudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 1, Induction Period 2: Double-blind Risankizumab 360mg SCSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV PboSubstudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IVSubstudy 2, Induction Period 2: Double-blind Risankizumab 180mg SCSubstudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC
NASOPHARYNGITISInfections and infestations4/595/623/615/5824/3412/364/371/716/718/32418/6533/1740/681/714/71
COLITIS ULCERATIVEGastrointestinal disorders5/591/623/611/5812/3411/361/370/713/7117/32410/6533/1741/683/710/71
ANAEMIABlood and lymphatic system disorders2/590/622/611/5812/3410/361/371/711/7119/32421/6535/1741/682/716/71
COVID-19Infections and infestations0/590/620/610/581/3410/360/370/710/7119/32430/65310/1744/684/716/71
HEADACHENervous system disorders3/592/623/614/5822/3412/360/372/715/717/32419/6533/1742/681/716/71
BRONCHITISInfections and infestations0/594/621/610/581/3410/360/370/710/710/3242/6531/1741/680/711/71
PHARYNGITISInfections and infestations1/591/620/610/583/3412/360/370/711/710/3240/6531/1740/680/710/71
SINUSITISInfections and infestations0/590/621/611/583/3412/360/370/712/711/3241/6530/1740/680/710/71
DRY SKINSkin and subcutaneous tissue disorders0/592/620/610/584/3412/360/370/711/712/3243/6530/1740/680/710/71
HAEMORRHOIDSGastrointestinal disorders3/590/620/610/580/3411/360/370/711/710/3245/6530/1740/681/711/71

Baseline characteristics

Includes all enrolled subjects that received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
Substudy 144.4 ± 14.0943.0 ± 14.9041.8 ± 13.8040.9 ± 13.7340.4 ± 14.17——42.5 ± 14.12
Substudy 2—————42.8 ± 14.3041.8 ± 13.4742.1 ± 13.75
Age, Customized
Age, Customized(Participants)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
Age Group — 18 - <4025273033175147313750
Age Group — 40 - <6529272720143153299698
Age Group — ≥656745222538107
Sex: Female, Male
Sex: Female, Male(Participants)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
Female24212627145124265632
Male36403531195201385923
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
Hispanic or Latino326121204497
Not Hispanic or Latino575955573193056061458
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
American Indian or Alaska Native00000011
Asian141115114796171365
Native Hawaiian or Other Pacific Islander00000000
Black or African American2112371228
White444945452902184611152
More than one race00000459
Unknown or Not Reported00000000
Adapted Mayo Score
Adapted Mayo Score(Adapted Mayo Score 0 - 9)Substudy 1, Induction Period 1: Double-blind Placebo IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IVSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IVSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IVSubstudy 2, Induction Period 1: Double-blind Placebo IVSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IVTotal
Substudy 1 - ITT1A Population7.012 ± 1.16456.929 ± 1.22407.011 ± 1.12887.150 ± 1.3908———7.024 ± 1.2240
Substudy 1 - ITT1B Population————7.179 ± 1.2279——7.179 ± 1.2279
Substudy 2 - ITT2 Population—————7.052 ± 1.28007.068 ± 1.21737.063 ± 1.2380
08

Study locations

430 sites
  • Southern California Res. Ctr. /ID# 169660
    Coronado, California 92118-1408, United States
  • Hoag Memorial Hosp Presbyterian /ID# 218348
    Irvine, California 92618, United States
  • UC San Diego Health System /ID# 160452
    La Jolla, California 92037, United States
  • United Medical Doctors /ID# 158528
    Los Alamitos, California 90720-3309, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 200931
    Los Angeles, California 90067-2001, United States
  • UCSF Center for Colitis and Crohn's Disease /ID# 201210
    San Francisco, California 94115-3011, United States
  • Cedars-Sinai Medical Center-West Hollywood /ID# 163851
    West Hollywood, California 90048, United States
  • Peak Gastroenterology Associates, PC /ID# 165841
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Pediatric Gastroenterology /ID# 207174
    Lone Tree, Colorado 80124-6798, United States
  • Medical Research Center of CT /ID# 160311
    Hamden, Connecticut 06518, United States
  • Yale Univ Digestive Diseases /ID# 213179
    New Haven, Connecticut 06510, United States
  • South Lake Pain Institute, Inc /ID# 162878
    Clermont, Florida 34711, United States
  • Ctr for Advanced Gastroenterol /ID# 202811
    Maitland, Florida 32751-6108, United States
  • University of Miami /ID# 160471
    Miami, Florida 33136, United States
  • Coral Research Clinic /ID# 158584
    Miami, Florida 33186-4643, United States
  • South Florida Research Ph I-IV, Inc. /ID# 161848
    Miami, Florida 33193, United States
  • Gastroenterology Group Naples /ID# 165212
    Naples, Florida 34102, United States
  • Advanced Research Institute, Inc /ID# 161938
    New Port Richey, Florida 34653, United States
  • Advent Health /ID# 160433
    Orlando, Florida 32803, United States
  • Endoscopic Research, Inc. /ID# 206711
    Orlando, Florida 32803, United States
  • Omega Research Group /ID# 203059
    Orlando, Florida 32808, United States
  • Lenus Research & Medical Group /ID# 169730
    Sweetwater, Florida 33172, United States
  • Clinical Research Trials of Florida, Inc. /ID# 201783
    Tampa, Florida 33607, United States
  • AdventHealth Tampa /ID# 170503
    Tampa, Florida 33613-4680, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 160523
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Spec /ID# 161372
    Suwanee, Georgia 30024, United States
  • The University of Chicago Medical Center /ID# 160521
    Chicago, Illinois 60637-1443, United States
  • DM Clinical Research/Southwest /ID# 165012
    Oak Lawn, Illinois 60453, United States
  • Indiana University /ID# 167252
    Indianapolis, Indiana 46202, United States
  • Univ Kansas Med Ctr /ID# 226602
    Kansas City, Kansas 66160, United States
  • Cotton-O'Neil Clinical Res Ctr /ID# 160412
    Topeka, Kansas 66606, United States
  • Robley Rex VA Medical Center /ID# 218648
    Louisville, Kentucky 40206, United States
  • Houma Digestive Health Special /ID# 158317
    Houma, Louisiana 70360, United States
  • Delricht Research /ID# 206815
    New Orleans, Louisiana 70115, United States
  • Nola Research Works, LLC /ID# 161368
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 201204
    Shreveport, Louisiana 71105-6800, United States
  • Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164255
    Boston, Massachusetts 02114, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 158524
    Ann Arbor, Michigan 48109, United States
  • Clin Res Inst of Michigan, LLC /ID# 160327
    Chesterfield, Michigan 48047, United States
  • Mayo Clinic - Rochester /ID# 200458
    Rochester, Minnesota 55905-0001, United States
  • Quality Clinical Research Inc. /ID# 167313
    Omaha, Nebraska 68114-3723, United States
  • Weill Cornell Medicine /ID# 165887
    New York, New York 10022, United States
  • Columbia Univ Medical Center /ID# 161934
    New York, New York 10032-3725, United States
  • Lenox Hill Hospital /ID# 168470
    New York, New York 10075, United States
  • Manhattan Clinical Research, LLC /ID# 211805
    New York, New York 10279, United States
  • DiGiovanna Institute for Medical Education & Research /ID# 171129
    North Massapequa, New York 11758, United States
  • University of Rochester Medical Center /ID# 161664
    Rochester, New York 14642, United States
  • Atrium Health Carolinas Medical Center /ID# 158512
    Charlotte, North Carolina 28203, United States
  • Carolina Research /ID# 201090
    Greenville, North Carolina 27834, United States
  • Plains Clinical Research Center, LLC /ID# 169732
    Fargo, North Dakota 58104-5925, United States
  • Cleveland Clinic Main Campus /ID# 209232
    Cleveland, Ohio 44195, United States
  • The Ohio State University /ID# 164714
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 167113
    Columbus, Ohio 43235, United States
  • Great Lakes Gastroenterology Research, LLC /ID# 201777
    Mentor, Ohio 44060-6211, United States
  • ProMedica Physicians Digestive Healthcare /ID# 215623
    Sylvania, Ohio 43560-2767, United States
  • Digestive Disease Specialists /ID# 170779
    Oklahoma City, Oklahoma 73112, United States
  • Adult Gastroenterology Associates - Gen 1 Research /ID# 208867
    Tulsa, Oklahoma 74136-7823, United States
  • Penn State Milton S. Hershey Medical Center /ID# 223563
    Hershey, Pennsylvania 17033-2360, United States
  • University of Pennsylvania /ID# 166266
    Philadelphia, Pennsylvania 19104-5502, United States
  • Digestive Disease Associates, LTD /ID# 232407
    Wyomissing, Pennsylvania 19610-2002, United States
  • Gastroenterology Associates, P.A. of Greenville /ID# 160472
    Greenville, South Carolina 29607, United States
  • Gastro One /ID# 160418
    Cordova, Tennessee 38018, United States
  • East Tennessee Research Institute /ID# 168747
    Johnson City, Tennessee 37604, United States
  • Vanderbilt University Medical Center /ID# 160580
    Nashville, Tennessee 37232-0011, United States
  • Inquest Clinical Research /ID# 165685
    Baytown, Texas 77521-2415, United States
  • Texas Digestive Disease Consultants /ID# 209950
    Cedar Park, Texas 78613-5028, United States
  • GI Alliance /ID# 209798
    Cedar Park, Texas 78613, United States
  • DHAT Research Institute /ID# 158226
    Garland, Texas 75044-2208, United States
  • Vilo Research Group Inc /ID# 207656
    Houston, Texas 77017-2337, United States
  • CliniCore International, LLC /ID# 158218
    Houston, Texas 77027-6812, United States
  • Baylor College of Medicine - Baylor Medical Center /ID# 158221
    Houston, Texas 77030-3411, United States
  • Precision Research Institute, LLC /ID# 201351
    Houston, Texas 77036, United States
  • Centex Studies, Inc. - Houston /ID# 201222
    Houston, Texas 77058, United States
  • Caprock Gastro Research, LLC /ID# 215432
    Lubbock, Texas 79424-3017, United States
  • Clinical Associates in Research Therapeutics of America, LLC /ID# 161376
    San Antonio, Texas 78212, United States
  • Southern Star Research Institute, LLC /ID# 168776
    San Antonio, Texas 78229-5390, United States
  • Baylor Scott & White Center for Diagnostic Medicine /ID# 204130
    Temple, Texas 76508, United States
  • Tyler Research Institute, LLC /ID# 166800
    Tyler, Texas 75701-4464, United States
  • Gastro Health & Nutrition - Victoria /ID# 164321
    Victoria, Texas 77904, United States
  • Advanced Research Institute /ID# 160480
    Ogden, Utah 84403, United States
  • Gastroenterology Consultants of Southwest Virginia /ID# 218143
    Roanoke, Virginia 24014-1372, United States
  • Virginia Mason Medical Center /ID# 160466
    Seattle, Washington 98101, United States
  • Gedyt /ID# 243423
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires 1115, Argentina
  • Cemic /Id# 167782
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires 1431, Argentina
  • Hospital Provincial del Centenario /ID# 170898
    Rosario, Santa Fe 2000, Argentina
  • Sanatorio 9 de Julio /ID# 167780
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Hospital Privado Univesitario /ID# 167779
    Cordoba, 5016, Argentina
  • Duplicate_Universitaetsklinikum St.Poelten /ID# 169048
    St. Poelten, Niederoesterreich 3100, Austria
  • Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 215320
    Linz, Oberoesterreich 4010, Austria
  • Medizinische Universitaet Graz /ID# 169053
    Graz, Steiermark 8010, Austria
  • Medizinische Universitaet Wien /ID# 169050
    Vienna, Wien 1090, Austria
  • Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 200685
    Salzburg, 5020, Austria
  • Cliniques Universitaires de Bruxelles Hopital Erasme /ID# 200252
    Brussels, Bruxelles-Capitale 1070, Belgium
  • UCL Saint-Luc /ID# 200039
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • CHU UCL Namur - site Godinne /ID# 200254
    Godinne, Namur 5530, Belgium
  • Universitair Ziekenhuis Leuven /ID# 170812
    Leuven, Vlaams-Brabant 3000, Belgium
  • AZ-Delta /ID# 200040
    Roeselare, West-Vlaanderen 8800, Belgium
  • Imelda Ziekenhuis /ID# 211100
    Bonheiden, 2820, Belgium
  • CHU de Liege /ID# 200253
    Liege, 4000, Belgium
  • Groupe Sante CHC - Clinique du MontLegia /ID# 200250
    Liege, 4000, Belgium

Showing the first 100 of 430 sites across 44 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Nov 2022, 56 months.

Results were first posted in Jan 2025, 2 years 2 months after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 12, 2018
StartActual
Mar 7, 2018
Primary completionActual
Nov 9, 2022
CompletionActual
May 11, 2023
Results delay requested
Jul 25, 2023
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03398148
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 12, 2018
Start date
Mar 7, 2018
Primary completion
Nov 9, 2022
Completion
May 11, 2023
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion